BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Osimertinib: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, CSPC Megalith Biopharmaceutical Co.,Ltd., Avistone Biotechnology Co., Ltd., Merus B.V., Shanghai JMT-Bio Inc., Klus Pharma Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoNon-Small Cell Lung Cancernot yet recruiting120
2026-12-12 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNSCLCnot yet recruiting680
2027-01-11 est.P3AstraZeneca AZNNCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGMetastatic Non-small Cell Lung Canceractive not recruiting768

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Avistone Biotechnology Co., Ltd.NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Non-Small-Cell Lung Cancerrecruiting120
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-09-30 est.P3Shanghai JMT-Bio Inc.NCT06735391 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic NonLocally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previourecruiting516
2026-08-31P2Klus Pharma Inc.NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Non-small Cell Lung Canceractive not recruiting356
2026-07-07P2AstraZeneca AZNNCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsLung Canceractive not recruiting76
2026-07-06P3AstraZeneca AZNNCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatCarcinoma; Non-Small-Cell Lungactive not recruiting341

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.